Sintx Technologies (LSE:0A8S) - Stock Price, News & Analysis

0A8S Stock Overview

0A8S fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 8.4% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 29.5% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($5M)

Highly volatile share price over the past 3 months

+ 2 more risks

Sintx Technologies, Inc. Competitors

Deltex Medical Group

AIM:DEMG

UK£2.6m

Surgical Innovations Group

AIM:SUN

UK£4.7m

NetScientific

AIM:NSCI

UK£15.1m

Belluscura

AIM:BELL

UK£12.8m

Price History & Performance

Summary of all time highs, changes and price drops for Sintx Technologies
Historical stock prices
Current Share Price	US$0.041
52 Week High	US$1.69
52 Week Low	US$0.022
Beta	1.42
1 Month Change	-17.44%
3 Month Change	-86.43%
1 Year Change	-97.39%
3 Year Change	-99.97%
5 Year Change	n/a
Change since IPO	-99.97%

Recent updates

Shareholder Returns

	0A8S	GB Medical Equipment	GB Market
7D	-7.1%	-2.0%	2.8%
1Y	-97.4%	-13.9%	1.1%

Return vs Industry: 0A8S underperformed the UK Medical Equipment industry which returned -13.9% over the past year.

Return vs Market: 0A8S underperformed the UK Market which returned 1.1% over the past year.

Price Volatility

Is 0A8S's price volatile compared to industry and market?
0A8S volatility
0A8S Average Weekly Movement	39.8%
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0A8S's share price has been volatile over the past 3 months.

Volatility Over Time: 0A8S's weekly volatility has increased from 26% to 40% over the past year.

About the Company

Founded	Employees	CEO	Website
1996	43	B. Bal	www.sintx.com

Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation.

Sintx Technologies, Inc. Fundamentals Summary

How do Sintx Technologies's earnings and revenue compare to its market cap?
0A8S fundamental statistics
Market cap	US$4.96m
Earnings (TTM)	-US$8.28m
Revenue (TTM)	US$2.63m

1.9x

P/S Ratio

-0.6x

P/E Ratio

Is 0A8S overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A8S income statement (TTM)
Revenue	US$2.63m
Cost of Revenue	US$784.00k
Gross Profit	US$1.84m
Other Expenses	US$10.13m
Earnings	-US$8.28m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.068
Gross Margin	70.16%
Net Profit Margin	-315.38%
Debt/Equity Ratio	0.5%

How did 0A8S perform over the long term?

See historical performance and comparison

0A8S Stock Overview

Rewards

Risk Analysis

Sintx Technologies, Inc. Competitors

AIM:DEMG

UK£2.6m

AIM:SUN

UK£4.7m

AIM:NSCI

UK£15.1m

AIM:BELL

UK£12.8m

Price History & Performance

Recent News & Updates

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Recent updates

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Insufficient new directors

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Insufficient new directors

Insufficient new directors

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Insufficient new directors

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Shareholder Returns

Price Volatility

About the Company

Sintx Technologies, Inc. Fundamentals Summary

1.9x

-0.6x

Earnings & Revenue